Pharmacoepigenetics of Vertigo and Related Vestibular Syndromes

Guerra, Joaquín; Cacabelos, Ramón

doi:10.1016/b978-0-12-813939-4.00028-0

Cited by 3 publications

(4 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, deficient levels of vitamin D can precipitate the development of cochlear impairment and hearing loss [26]. Previous reports demonstrated that vitamin D deficiency and genetic alterations in VDRs were correlated significantly with impaired ear development, incidental cochlear hearing loss, SNHL, otosclerosis, and vestibular disorders [27,28]. Thus, it is logical to consider vitamin D deficiency as a critical contributor to hearing impairment in T2DM patients, Such theory is supported by the findings of our study in which we found a significant correlation between serum 25OHD level and degree of impairment in T2DM patients; patients with hearing impairment exhibited a lower level of serum 25OHD than patients with normal audiometer findings.…”

Section: Discussionmentioning

confidence: 99%

Hearing impairment in relation to vitamin D status in type 2 diabetic patients: A cross-sectional study

Elhussieny,

Eladawy,

Ahmad

et al. 2023

ELECTRON J GEN MED

View full text Add to dashboard Cite

Objectives: To evaluate the association of serum 25 hydroxy vitamin D (25OHD) and hearing impairment type 2 diabetes mellitus (T2DM) patients. In addition, we aimed to examine whether T2DM-associated hearing impairment is correlated with the severity of diabetes. Methods: The present case-control study recruited adult patients with T2DM and healthy controls. Using pure-tone stimuli, we used an audiometer to assess the hearing thresholds of air conduction in each ear separately. Results: 84 patients and 32 volunteers were included. The serum 25OHD was lower in T2DM patients than in healthy control (12.24±1.3 versus 23.19±5.69, respectively; p<0.001). The prevalence of vitamin D deficiency was 100% in the T2DM group, compared to 25% in the control group (p=0.001). T2DM patients exhibited higher hearing thresholds at all tested frequencies compared to the control group (p<0.001). Diabetic patients with hearing impairment had a significantly lower serum 25OHD than the normal hearing group (11.7±1.2 versus 12.6±1.2 ng/d; p=0.02). The multivariate analysis demonstrated that serum 25OHD level was an independent predictor of hearing loss among diabetic patients (β=-0.605; p=0.041). Conclusions: the present study highlights the potential role of vitamin D deficiency in developing hearing impairment in the setting of T2DM. We found a negative correlation between serum 25OHD level and air conduction thresholds at low-mid and high frequencies amongst patients with T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Hearing impairment in relation to vitamin D status in type 2 diabetic patients: A cross-sectional study

Elhussieny,

Eladawy,

Ahmad

et al. 2023

ELECTRON J GEN MED

View full text Add to dashboard Cite

show abstract

“…By contrast, in other disorders such as chronic vestibular hypofunction or age-related hearing loss, there is a deterioration of sensory and neural activity ( Peelle and Wingfield, 2016 ). The neurochemistry of these audiovestibular disorders includes diverse neurotransmitters with excitatory (glutamate, acetylcholine), inhibitory (GABA, glycine), modulatory (histamine, noradrenaline) and other actions (enkephalin, motilin, somatostatin, dopamine and serotonin) ( Guerra and Cacabelos, 2019 ). As a result, and depending on the case, therapeutic approaches differ, with depressive drugs administered in cases of increased neuronal excitability, and stimulants prescribed in cases of decreased neuronal activity.…”

Section: Introductionmentioning

confidence: 99%

“…One of the potential consequences of using pharmacogenomics in clinical trials and molecular therapeutics is that a given disease may be treated based on genomic and biological markers, selecting drugs optimized for individual patients or for groups of patients with similar genomic profiles. This aspect has been little explored in the scientific literature ( Guerra and Cacabelos, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Potential effects of cannabinoids on audiovestibular function: A narrative review

2022

View full text Add to dashboard Cite

The growing interest in the development of drugs that target the endocannabinoid system has extended to conditions that affect the audiovestibular pathway. The expression of cannabinoid (CB) receptors in that pathway has been widely demonstrated, indicating a therapeutic potential for drug development at this level. These medications may be beneficial for conditions such as noise-induced hearing loss, ototoxicity, or various forms of vertigo of central or peripheral origin. The therapeutic targets of interest include natural or synthetic compounds that act as CB1/CB2 receptor agonists/antagonists, and inhibitors of the endocannabinoid-degrading enzymes FAAH and MAGL. Furthermore, genetic variations implicated in the response to treatment and the development of related disorders such as epilepsy or migraine have been identified. Direct methods of administering these medications should be examined beyond the systemic strategy.

show abstract

“…Vestibular syndromes imply that metabolic factors may act in their development, such as (1) multiple neurotransmitters with different effects: excitatory (glutamate, dopamine, and serotonin), modulating (histamine and enkephalins), or inhibitory (GABA and glycine); (2) inflammatory cytokines (TNF and IL3); (3) reactive oxygen species (ROS); and (4) other factors [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Melatonin Exerts Anti-Inflammatory, Antioxidant, and Neuromodulatory Effects That Could Potentially Be Useful in the Treatment of Vertigo

Guerra¹,

Devesa²

2021

International Journal of Otolaryngology

View full text Add to dashboard Cite

The acute phase of vertigo involves multiple neurotransmitters, inflammatory mediators, and products of oxidative stress. The vestibular pathway has multiple melatonin receptors distributed along its path, both centrally and peripherally. In addition, melatonin has been shown to be a powerful antioxidant and anti-inflammatory agent against factors related to vertigo, such as Bax/caspases, interleukins, and chemokines. Likewise, it exerts central GABAergic, antidopaminergic, and anti-migraine functions and regulates sympathetic activity in a similar way to the drugs classically used in acute vestibular crisis. In this review, the role of melatonin as a potential treatment of the acute phase of vertigo is discussed.

show abstract

Pharmacoepigenetics of Vertigo and Related Vestibular Syndromes

Cited by 3 publications

References 96 publications

Hearing impairment in relation to vitamin D status in type 2 diabetic patients: A cross-sectional study

Hearing impairment in relation to vitamin D status in type 2 diabetic patients: A cross-sectional study

Potential effects of cannabinoids on audiovestibular function: A narrative review

Melatonin Exerts Anti-Inflammatory, Antioxidant, and Neuromodulatory Effects That Could Potentially Be Useful in the Treatment of Vertigo

Contact Info

Product

Resources

About